title: von Willebrand factor without the A2 domain is resistant to proteolysis.
abstract: von Willebrand factor (vWF) is a complex multimeric plasma glycoprotein, that plays a critical role in the mediation of platelet adhesion to the damaged vascular wall, and functions as a carrier protein for factor VIII. vWF has a domain structure consisting of repeated A, B, C, and D domains. The A1 domain is involved in binding to the platelet receptor glycoprotein (GP) Ib, and the A3 domain has a binding site for collagen. A function of the A2 domain has not been described, although point mutations identified in von Willebrand disease (vWD) type 2A patients are localized in this domain. To study the role of the A2 domain a deletion mutant was constructed which lacked the A2 domain, delta A2-vWF. Previous studies have shown that this approach is a powerful tool to study the function of a domain in a protein since it does not affect the activity of other domains. After expression in baby hamster kidney (BHK) cells, delta A2-vWF was compared to wild-type (WT) vWF, and to delta A1-vWF (Lankhof et al., Blood 86: 1035, 1995). Ristocetin induced platelet binding was slightly increased but botrocetin induced platelet binding was normal as was binding to heparin and collagen type III. Adhesion studies to surface coated purified delta A2-vWF or to delta A2-vWF preincubated on collagen under flow conditions showed no abnormalities. Incubation with normal human plasma showed that delta A2-vWF like WT-vWF was not sensitive to proteolysis. After addition of urea, WT-vWF becomes sensitive to the protease, indicating that unfolding of the molecule is necessary for exposure of the cleavage site. delta A2-vWF tested under the same conditions was resistant, indicating that the protease sensitive site is located in the A2 domain.
authors.affiliation: Department of Haematology, University Hospital Utrecht, The Netherlands.
authors.forename: H
authors.initials: H
authors.lastname: Lankhof
authors.forename: C
authors.initials: C
authors.lastname: Damas
authors.forename: M E
authors.initials: ME
authors.lastname: Schiphorst
authors.forename: M J
authors.initials: MJ
authors.lastname: Ijsseldijk
authors.forename: M
authors.initials: M
authors.lastname: Bracke
authors.forename: M
authors.initials: M
authors.lastname: Furlan
authors.forename: H M
authors.initials: HM
authors.lastname: Tsai
authors.forename: P G
authors.initials: PG
authors.lastname: de Groot
authors.forename: J J
authors.initials: JJ
authors.lastname: Sixma
authors.forename: T
authors.initials: T
authors.lastname: Vink
mesh_terms: D000818:Animals; D001792:Blood Platelets / Q000187:drug effects / Q000502:physiology; D002460:Cell Line; D003094:Collagen / Q000494:pharmacology; D006224:Cricetinae; D003435:Crotalid Venoms / Q000494:pharmacology; D006388:Hemagglutinins / Q000494:pharmacology; D006801:Humans; D007668:Kidney; D007700:Kinetics; D046911:Macromolecular Substances; D016297:Mutagenesis, Site-Directed; D010973:Platelet Adhesiveness / Q000187:drug effects; D011994:Recombinant Proteins / Q000737:chemistry / Q000378:metabolism; D012310:Ristocetin / Q000494:pharmacology; D017384:Sequence Deletion; D014162:Transfection; D014841:von Willebrand Factor / Q000737:chemistry* / Q000378:metabolism*
chemical_list: D003435:Crotalid Venoms; D006388:Hemagglutinins; D046911:Macromolecular Substances; D011994:Recombinant Proteins; D014841:von Willebrand Factor; D012310:Ristocetin; C030961:botrocetin; D003094:Collagen